Highest-materiality recent filing
BioMarin Q1 revenue up 3% to $766M; EPS down; raises FY2026 guidance to $3.825-$3.925B
Total revenues $766M (+3% YoY); GAAP net income $106M (down 43%) vs $186M.
BioMarin completes $4.8B acquisition of Amicus Therapeutics; adds Galafold, Pombiliti+Opfolda
Acquired Amicus for $14.50/share in cash; total equity value ~$4.8B.
BioMarin receives French FDI clearance for Amicus merger; closing expected April 27, 2026
French Ministry of Economics and Finance granted FDI clearance for merger with Amicus on April 23, 2026.
BioMarin discontinues VOXZOGO trials in Turner, SHOX, ACAN after SCFE safety events
Discontinued dosing and enrollment in Phase 2 CANOPY trials for Turner syndrome, SHOX-deficiency, and ACAN-deficiency.
BioMarin Q4 rev $875M (+17% Y/Y); GAAP net loss $47M on ROCTAVIAN withdrawal; Amicus deal on track
Q4 total revenues $875M (+17% Y/Y); full-year $3.22B (+13% Y/Y).
BioMarin closes $850M 5.500% senior notes offering to fund Amicus acquisition
Closed private placement of $850M 5.500% senior notes due 2034 at 100% issue price.
BioMarin prices $850M 5.500% notes due 2034 and syndicates $2B term loan for Amicus acquisition
$850M 5.500% senior notes due 2034; price 100%; expected close Feb 12, 2026.
BioMarin guides ~$3.2B FY2025 revenue; plans $850M notes + $2.8B loans for Amicus deal
FY2025 preliminary total revenue ~$3.2B, including ~$920M from VOXZOGO; cash & investments ~$2.1B.
BioMarin estimates FY2025 revenue ~$3.2B; expects $230-260M ROCTAVIAN asset write-down
Preliminary FY2025 total revenue ~$3.2B, with VOXZOGO contributing ~$920M.
BioMarin ends development of oral AATD liver disease candidate BMN 349
Discontinued BMN 349, an oral therapeutic for alpha-1 antitrypsin deficiency (AATD)-associated liver disease.
BioMarin to acquire Amicus Therapeutics for $4.8B in all-cash deal at $14.50/share
BioMarin acquires Amicus for $14.50/share in cash, total equity value ~$4.8B; expected Q2 2026 close.
BioMarin appoints Rashmi Ramchandani as Chief Accounting Officer, effective Jan 19, 2026
Ramchandani becomes VP, Chief Accounting Officer and principal accounting officer; CFO Brian Mueller remains principal financial officer.
BioMarin Q3 net loss $31M vs income $106M YoY; revenue +4% to $776M; guidance raised
GAAP net loss of $31M (diluted EPS -$0.16) vs income $106M ($0.55) in Q3 2024, due to $221M IPR&D charge from Inozyme acquisition.
BioMarin expects $221M IPR&D charge from Inozyme acquisition, ~$1.10 EPS hit in Q3 2025
Acquired IPR&D charge of ~$221M pre-tax from July 1 Inozyme Pharma acquisition.
Erin Burkhart notified her resignation as Chief Accounting Officer, effective September 2, 2025; departure is voluntary with no disagreement.
BioMarin Q2 revenue $825M (+16% Y/Y); GAAP EPS $1.23 (+124%); raises full-year guidance
Total revenue $825M, +16% Y/Y; GAAP net income $241M (vs $107M) and diluted EPS $1.23 (+124%).
BioMarin appoints Ian T. Clark to Board of Directors effective August 1, 2025
Board size increased from ten to eleven members to accommodate Clark's appointment.
BioMarin shareholders approve 8M share increase in equity plan, re-elect all directors
Shareholders approved 8M additional shares under the 2017 Equity Incentive Plan (157.3M for, 7.7M against).
BioMarin acquires Inozyme for $4.00/share (~$270M cash); adds late-stage ENPP1 therapy
All-cash tender offer at $4.00 per share; total equity value ~$270M; expected to close Q3 2025.
BioMarin Q1 2025 revenue $745M (+15% YoY), GAAP EPS $0.95, reaffirms 2025 guidance
Q1 total revenues $745M (+15% Y/Y); GAAP net income $186M (+109% Y/Y); non-GAAP income $221M (+58% Y/Y).
BioMarin amends bylaws to adopt majority voting for directors and tighten advance notice provisions
Uncontested director elections now require 'for' votes to exceed 'against' votes (majority voting standard).
BioMarin appoints Timothy Walbert to board, expanding size to 12 members
Board increased from 11 to 12 members; Walbert appointed effective February 24, 2025.
BioMarin reports Q4 revenue $747M (+16%), full-year GAAP EPS $2.21, guides 2025 rev growth ~10%
Q4 total revenue $747M (+16% YoY); full-year $2.854B (+18%). GAAP diluted EPS $0.64 (Q4) and $2.21 (FY), up 154% YoY.
BioMarin Q3 revenue $746M (+28% YoY), GAAP EPS $0.55 (+162%), raises FY2024 guidance
Total revenues $746M (+28% YoY); VOXZOGO revenue +54% YoY; enzyme therapies +27%.
BioMarin reaffirms long-term guidance: ~$4B revenue by 2027, 40% margin from 2026
Reaffirms ~$4B total revenues in 2027.
BioMarin enters $600M revolving credit facility maturing 2029, undrawn at closing
Entered $600M revolving credit facility with Citibank as administrative agent.
BioMarin to cut ~225 jobs, incur $30-35M in severance costs by end of 2024
Workforce reduction of ~225 employees committed on Aug 23, 2024, in organizational redesign.
BioMarin R&D chief Henry Fuchs to retire March 2025; Greg Friberg to succeed
Dr. Henry J. Fuchs to retire from BioMarin effective March 3, 2025.
BioMarin Q2 revenue $712M (+20% YoY), GAAP EPS $0.55 (+90%), raises FY2024 guidance
VOXZOGO revenue $183.9M (+62% YoY); ~3,500 children on treatment across 44 countries.
BioMarin shareholders elect all director nominees, ratify KPMG, approve say-on-pay
All 11 director nominees elected; highest vote count 152.1M for Barbara Bodem, lowest 143.7M for Elizabeth Anderson.
BioMarin to cut ~170 jobs, book $15-20M charge from R&D program exits
Strategic portfolio assessment led to discontinuation of certain R&D programs.
the Board of Directors (the “Board”) of BioMarin Pharmaceutical Inc. (the “Company”) increased the size of the Board from eleven to twelve members and appointed Timothy P. Walbert to the Board, to be effective February 24, 2025.
On August 16, 2024, Dr. Henry J. Fuchs advised BioMarin Pharmaceutical Inc. (the “Company”) that he has elected to retire from the Company effective March 3, 2025 (the “Retirement Date”).
He will continue in his current role until Dr. Greg Friberg assumes the position of Executive Vice President, Chief Worldwide Research and Development Officer, which is expected on September 30, 2024.
Max materiality 0.90 · Median 0.75 · Most common event earnings